Thursday morning NovoCure (NVCR 3.47%) published its first set of quarterly results for 2025, and they pleased more than a few investors. With that tailwind, the biotech's stock price rose in excess of 4%, easily topping the slightly over 2% increase of the S&P 500 index.
A double beat for the inaugural quarter
For the first quarter, NovoCure recorded net revenue that was just shy of $155 million. That was a nearly 12% improvement over the same period of 2024. Compounding that, the biotech managed to narrow its generally accepted accounting principles (GAAP) net loss by roughly the same percentage; it landed at $34.4 million ($0.31 per share) against the Q1 2024 shortfall of $38.8 million.
As a group, analysts tracking NovoCure's fortunes weren't expecting the company to do so well. Their collective estimate for net revenue was under $148 million; for headline net loss it was $0.49 per share.
Although NovoCure is one of a big clutch of biotechs developing cancer therapies, it's unique in the segment. Its money technology is tumor treating fields (TTFs), which as the name suggests are electrical fields produced by a small device powered by a battery. These fields hold the promise of treating various cancers without the often heavy side effects of other therapies.
NASDAQ: NVCR
Key Data Points
Future expansion
NovoCure is also making a concentrated effort to branch out, an effort that's clearly appreciated by the market. It quoted CEO Ashley Cordova as saying that "our footprint is expanding across new indications, new centers, and new physician specialties."
I'm not sure TTFs will become the go-to oncology treatment in the market, but the technology sure is intriguing and well worth watching. NovoCure stock is worth considering on that basis, in my view.
